JP6186440B2 - キナーゼ阻害剤としてのジヒドロピロリジノピリミジン - Google Patents

キナーゼ阻害剤としてのジヒドロピロリジノピリミジン Download PDF

Info

Publication number
JP6186440B2
JP6186440B2 JP2015533126A JP2015533126A JP6186440B2 JP 6186440 B2 JP6186440 B2 JP 6186440B2 JP 2015533126 A JP2015533126 A JP 2015533126A JP 2015533126 A JP2015533126 A JP 2015533126A JP 6186440 B2 JP6186440 B2 JP 6186440B2
Authority
JP
Japan
Prior art keywords
alkyl
cancer
cycloalkyl
membered
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015533126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529248A5 (enExample
JP2015529248A (ja
Inventor
ディロン，ミッチェル，パトリック
リンドヴァール，ミカ
プーン，ダニエル
ラマーシー，サビスリ
ラウニヤー，ビベック
シェーファー，シンシア
スブラマニアン，シャラドハ
タナー，フー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2015529248A publication Critical patent/JP2015529248A/ja
Publication of JP2015529248A5 publication Critical patent/JP2015529248A5/ja
Application granted granted Critical
Publication of JP6186440B2 publication Critical patent/JP6186440B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015533126A 2012-09-19 2013-09-17 キナーゼ阻害剤としてのジヒドロピロリジノピリミジン Active JP6186440B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702981P 2012-09-19 2012-09-19
US61/702,981 2012-09-19
PCT/US2013/060032 WO2014047020A1 (en) 2012-09-19 2013-09-17 Dihydropyrrolidino-pyrimidines as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2015529248A JP2015529248A (ja) 2015-10-05
JP2015529248A5 JP2015529248A5 (enExample) 2017-08-17
JP6186440B2 true JP6186440B2 (ja) 2017-08-23

Family

ID=49274870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015533126A Active JP6186440B2 (ja) 2012-09-19 2013-09-17 キナーゼ阻害剤としてのジヒドロピロリジノピリミジン

Country Status (13)

Country Link
US (1) US9546173B2 (enExample)
EP (1) EP2897961B1 (enExample)
JP (1) JP6186440B2 (enExample)
KR (1) KR20150056550A (enExample)
CN (1) CN104640865B (enExample)
AU (1) AU2013318283A1 (enExample)
BR (1) BR112015005982A2 (enExample)
CA (1) CA2882410A1 (enExample)
EA (1) EA201590600A1 (enExample)
ES (1) ES2612885T3 (enExample)
IN (1) IN2015DN01328A (enExample)
MX (1) MX2015003535A (enExample)
WO (1) WO2014047020A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013318283A1 (en) * 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
CA3103711A1 (en) 2018-07-12 2020-01-16 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
WO2020243457A1 (en) * 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
CN114502546A (zh) * 2019-08-01 2022-05-13 普拉特戈公司 晚期糖基化终产物的抑制剂
KR20220112777A (ko) * 2019-12-10 2022-08-11 에프. 호프만-라 로슈 아게 패러독스 파괴제로서의 새로운 braf 억제제
FI4073065T3 (fi) 2019-12-10 2025-04-16 Hoffmann La Roche Uusia metyylikinatsolinonijohdannaisia
CA3177298C (en) * 2020-04-30 2023-11-21 Xile LIU Compounds containing benzosultam as erk inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4530852B2 (ja) * 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2004313928A1 (en) * 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
KR100919343B1 (ko) 2005-01-10 2009-09-25 화이자 인코포레이티드 키네이스 억제제로서 피롤로피라졸
RU2442778C9 (ru) 2005-12-13 2012-08-10 Шеринг Корпорейшн Новые соединения, действующие как ингибиторы erk
AR068046A1 (es) 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) * 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012065935A1 (en) 2010-11-17 2012-05-24 F. Hoffmann-La Roche Ag Methods of treating tumors
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
CN104507936A (zh) 2012-03-02 2015-04-08 基因科技股份有限公司 吡啶基和嘧啶基亚砜和砜衍生物
AU2013318283A1 (en) * 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors

Also Published As

Publication number Publication date
MX2015003535A (es) 2015-07-14
BR112015005982A2 (pt) 2017-07-04
CA2882410A1 (en) 2014-03-27
WO2014047020A1 (en) 2014-03-27
CN104640865A (zh) 2015-05-20
KR20150056550A (ko) 2015-05-26
US20150274733A1 (en) 2015-10-01
IN2015DN01328A (enExample) 2015-07-03
EP2897961A1 (en) 2015-07-29
ES2612885T3 (es) 2017-05-19
EA201590600A1 (ru) 2015-07-30
AU2013318283A1 (en) 2015-03-05
CN104640865B (zh) 2018-05-11
US9546173B2 (en) 2017-01-17
JP2015529248A (ja) 2015-10-05
EP2897961B1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
CN104379575B (zh) 用于调节egfr活性的化合物和组合物
EP2897961B1 (en) Dihydropyrrolidino-pyrimidines as kinase inhibitors
CA2828478A1 (en) Serine/threonine kinase inhibitors
CN116685585B (zh) 一种高活性的hpk1激酶抑制剂
EP3371166A1 (en) 1,4-dicarbonyl-piperidyl derivatives
EP3840747B1 (en) Novel aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
TWI914410B (zh) 雜芳基雜環化合物及其用途
CN116848115B (zh) Wnt通路抑制剂化合物
JP2025527934A (ja) ピラゾリルスルホンアミド化合物、及び療法におけるそれらの使用
WO2024044344A1 (en) Pyridinylsulfonamide compounds and their use in therapy
TWI768781B (zh) 轉化生長因子－β受體抑制劑
TW202304906A (zh) 高活性hpk1激酶抑制劑
TWI924689B (zh) 嘧啶酮類化合物及其用途
WO2025072437A1 (en) Heteroaryl compounds and their use in treating medical conditions
HK40129802A (zh) 杂芳基杂环化合物及其用途
HK40130478A (zh) 杂芳基杂环化合物及其用途
CA2989684C (en) Hpk1 inhibitors and methods of using same
HK40130202A (zh) 杂芳基杂环化合物及其用途
HK40094658B (zh) 杂芳基杂环化合物及其用途
HK40094658A (zh) 杂芳基杂环化合物及其用途
WO2024059559A1 (en) Isothiazolylcarboxamide compounds and their use in therapy
HK40091563B (zh) 嘧啶酮类化合物及其用途
HK40091563A (zh) 嘧啶酮类化合物及其用途
JP2023538097A (ja) ピリミジノン化合物およびその使用
HK1255833B (en) Hpk1 inhibitors and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170420

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170731

R150 Certificate of patent or registration of utility model

Ref document number: 6186440

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250